Sponsors
The bill trades stronger protections against fraud and clearer billing rules (which can save Medicare dollars and improve oversight) for greater access friction and compliance costs—potentially delaying needed care and imposing administrative burdens on providers, especially smaller practices.
Taxpayers and Medicare beneficiaries will likely see reduced improper payments, fraud, and waste because the bill narrows when high‑cost durable medical equipment (DME) and lab tests can be ordered via telehealth and requires provider NPIs on telehealth claims.
Providers and payers will have clearer billing rules and improved claim traceability because CMS must define which high‑cost DME and lab tests are covered and telehealth claims must include the ordering provider's assigned NPI.
Medicare patients with chronic conditions may get stronger clinical oversight and improved patient safety because the policy encourages in‑person evaluations before ordering expensive equipment or tests.
Medicare beneficiaries may face reduced or delayed access to needed high‑cost DME and lab tests if they cannot obtain timely in‑person visits, which can worsen outcomes for people who rely on quick telehealth access.
Healthcare providers—especially small practices—will incur administrative and IT costs, increased audit/compliance risk, and may experience denied payments or lost revenue if they do not update billing systems and workflows to meet new NPI and documentation requirements within the 180‑day window.
Medicare beneficiaries risk denied claims and unexpected out‑of‑pocket costs if CMS defines covered items/tests in ways that exclude items previously obtainable via telehealth.
Based on analysis of 3 sections of legislative text.
Introduced March 3, 2025 by Lloyd Alton Doggett · Last progress March 3, 2025
Prohibits Medicare payment for high-cost durable medical equipment and high-cost laboratory tests ordered solely via telehealth unless the ordering clinician saw the beneficiary in person at least once within the prior six months, with the rule taking effect 180 days after enactment. Directs CMS to define and list which DME and lab tests are "high-cost," requires Medicare Administrative Contractors to audit providers who order almost all such items via telehealth, and requires providers to submit telehealth claims using their NPI or face payment denial after 180 days.